Source: resolution_news Source ID: resolution_news:9e7979d857f9be267db66b65e1ac4280:ZYME URL: https://news.google.com/rss/articles/CBMi1AFBVV95cUxPRDZybFkyLXE2dVFPWlVkWkZEby0tVTZHaVRQUTZETVVNRzJITTMtZF85NUxRU1hmZUJid3NETTFZR0NtNlJKTmdDVlFUTWtqNFBuZFQtTDI1Qmc5SGRZMThrOGNOeEpEN25IamxvRnYzMFVHaDVpM0FZSldPTGhkZEdCQ1BHOEpuNk9pYXNHMG1MS1RMbHkxX3VVVlFibEhWTVVUUzZGOUY0U2JUUkE2dVRKWFJ2WkZjUWt5UXFJVEY2QjJHM3RDM2tBQXBESnlxSHBDSQ?oc=5 Symbol: (ZYME) Published: 2026-08-31 03:00:00 EDT Time precision: minute Title: Zanidatamab Plus Chemotherapy Improves OS at Second Interim Analysis of HERIZON-GEA-01 in First-Line HER2+ GEA - OncLive Zanidatamab Plus Chemotherapy Improves OS at Second Interim Analysis of HERIZON-GEA-01 in First-Line HER2+ GEA OncLive